Infliximab in the treatment of psoriasis

Emily Becker, John Y.M. Koo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Infliximab, manufactured as Remicade by Centocor Inc. (Malvern, Pennsylvania, USA), is the only intravenously infused biologic agent approved for the treatment of adults with chronic severe plaque-type psoriasis. The family of biologic agents currently approved for this more extensive and often times debilitating type of psoriasis includes infliximab, alefacept, efalizumab, etanercept, and adalimumab.

Original languageEnglish (US)
Title of host publicationModerate-to-Severe Psoriasis, Third Edition
PublisherCRC Press
Pages289-305
Number of pages17
ISBN (Electronic)9781420088687
ISBN (Print)142008867X, 9781420088670
StatePublished - Jan 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Infliximab in the treatment of psoriasis'. Together they form a unique fingerprint.

Cite this